Semaglutide in Canada: ingredient and product guide

One ingredient, three branded product contexts

Ozempic is an injectable product centred on type 2 diabetes and defined risk-reduction uses. Wegovy is an injectable product with several current indications, including chronic weight management. Rybelsus is an oral type 2 diabetes product.

The ingredient helps explain shared mechanism; the product monograph controls indications, instructions, contraindications and warnings.^[1][2][3]

Generic authorization does not settle availability or price

Health Canada authorized the first generic semaglutide products in 2026. The generic semaglutide update records the product and indication milestones. Pharmacy stock, substitution, presentation and insurance still require current checks.^[4][5][6]

Why semaglutide products are not casually interchangeable

Route, formulation, concentration, schedule, indication and instructions differ. Do not transfer dose or missed-dose assumptions between products. A prescriber and pharmacist must manage any product change.